Pharmaxis Receives UK Approval For Phase III Cystic Fibrosis Trial

Specialist pharmaceutical company Pharmaxis Ltd (ASX: PXS; Nasdaq: PXSL) has received approval from the U.K. Medicines Healthcare products Regulatory Agency (MHRA) to begin the UK arm of an international Phase III clinical trial to evaluate Bronchitol in patients suffering from cystic fibrosis. Alan...